➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Mallinckrodt
Harvard Business School
McKesson
Dow

Last Updated: September 23, 2020

DrugPatentWatch Database Preview

Patent: 5,750,398

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,750,398
Title: Vector, element and method for inhibiting immune recognition
Abstract:This invention relates to the use of Herpes Simplex Virus (HSV) immediate early protein ICP47, nucleic acid sequences coding for ICP47, and homologous proteins and nucleic acid sequences, to inhibit presentation of viral and cellular antigens associated with major histocompatibility class I (MHC class I) proteins to CD8+ T lymphocytes; this inhibition effectively increases infective persistence, which can, for example, improve the utility of viral gene therapy vectors. This invention also pertains to a method for the treatment of herpesvirus infections, wherein expression and/or activity of the ICP47 protein or its homologue is inhibited in order to increase immune recognition of herpesvirus-infected cells and other cells. This invention also pertains to a method for identifying drugs that interfere with the expression or function of ICP47 and its homologues, and which are useful in treating herpesvirus infections, and also pertains to the drugs so identified. Furthermore, this invention pertains to methods for the treatment and prevention of autoimmune diseases, tissue and organ transplant rejection, diabetes, multiple sclerosis, arthritis, and tissue damage accompanying ocular herpesvirus infections, wherein ICP47 or its homologue, or nucleic acids encoding such proteins, are introduced into the cells of a patient. In addition, this invention pertains to vector elements, vectors, polypeptides and polypeptide fragments that can be utilized for the forgoing purposes.
Inventor(s): Johnson; David C. (Hamilton, Ontario, CA), York; Ian A. (Hamilton, Ontario, CA)
Assignee: Johnson; David C. (Portland, OR) York; Ian A. (Worcester, MA)
Application Number:08/159,890
Patent Claims:see list of patent claims

Details for Patent 5,750,398

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Johnson; David C. (Portland, OR) York; Ian A. (Worcester, MA) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Johnson; David C. (Portland, OR) York; Ian A. (Worcester, MA) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Johnson; David C. (Portland, OR) York; Ian A. (Worcester, MA) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Medtronic
Boehringer Ingelheim
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.